Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

This study is testing whether combining low-dose radiation therapy with an immunotherapy drug (anti-PD-1) before surgery can shrink locally advanced head and neck squamous cell cancer more effectively, making surgery more successful. **You may be eligible if...** - You are between 18 and 75 years old - You have been newly diagnosed with stage III–IVB squamous cell carcinoma of the mouth, throat, or voice box - You have not yet received any treatment for this cancer - You are in good physical condition (ECOG 0 or 1) - Your cancer is considered operable based on your surgeon's assessment - Your blood counts, organ function, and thyroid levels meet required thresholds **You may NOT be eligible if...** - You have already received treatment for head and neck cancer - You have a history of serious autoimmune disease or organ/stem cell transplant - You are HIV-positive or have untreated active hepatitis B or C - You are pregnant or unwilling to use effective contraception - You have uncontrolled heart disease or other serious conditions Talk to your doctor to see if this trial is right for you.